Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 2010

View Archived Issues

Bruton's tyrosine kinase inhibitors reported by CGI and Genentech

Multikinase inhibitor regorafenib evaluated in NSCLC; interim phase I data presented

Maximum tolerated dose of acadesine identified in chronic lymphocytic leukemia patients

Genetic variations linked to pancreatic cancer risk

Brivaracetam dose adjustment not needed for renal dysfunction

SBR-759 superior to sevelamer HCI for hyperphosphatemia in Asian hemodialysis patients

Transition Therapeutics begins phase I study of TT-301 for CNS indications

Pfizer claims cholecystokinin-1 agonists for obesity and co-morbidities

Novel PDE5A inhibitors claimed by Chinese scientists

Janssen claims rifamycin derivatives as antibacterials

M3 receptor antagonists under study at Argenta and AstraZeneca

Myriad Pharmaceuticals changes name to Myrexis, will focus on oncology programs

Sepracor's Omnaris HFA meets primary endpoint in phase III study

Strativa receives FDA approval for Zuplenz oral soluble film

ADVENTRX reports encouraging 9-month data from stability tests of Exelbine

BioSante reports results from phase II study of its Pill-Plus oral contraceptive

FDA approves Purdue Pharma's Butrans transdermal system CIII for chronic pain

Corcept begins dosing in phase III study of Corlux in Cushing's syndrome

AstraZeneca and MRC Technology form alliance to share compound libraries

Circadin approved in the E.U. for 13-week treatment for primary insomnia

X-Chem and Roche collaborate on drug discovery

Alimera submits NDA to the FDA for Iluvien in diabetic macular edema

Cell Therapeutics files updated Pediatric Investigation Plan for pixantrone to the EMA

MorphoSys receives grant from German government for MOR-202 cancer program

Clemizole may yield high-level synergy with protease inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...